917,692 Shares in ImageneBio, Inc. $IMA Purchased by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP acquired a new position in shares of ImageneBio, Inc. (NASDAQ:IMA) in the 2nd quarter, HoldingsChannel reports. The firm acquired 917,692 shares of the company’s stock, valued at approximately $5,414,000. ImageneBio makes up approximately 0.8% of Blue Owl Capital Holdings LP’s holdings, making the stock its 22nd largest position. Blue Owl Capital Holdings LP owned about 0.09% of ImageneBio at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in IMA. BlackRock Inc. acquired a new stake in shares of ImageneBio in the second quarter worth approximately $797,000. Rangeley Capital LLC raised its stake in ImageneBio by 78.6% in the 1st quarter. Rangeley Capital LLC now owns 32,590 shares of the company’s stock valued at $163,000 after purchasing an additional 14,346 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in ImageneBio by 23.6% in the 1st quarter. Renaissance Technologies LLC now owns 81,696 shares of the company’s stock valued at $408,000 after purchasing an additional 15,600 shares in the last quarter. BML Capital Management LLC boosted its stake in ImageneBio by 13.4% during the 1st quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock worth $1,004,000 after purchasing an additional 23,704 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in ImageneBio during the 4th quarter worth $233,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Stock Down 1.4%

IMA stock opened at $5.61 on Friday. ImageneBio, Inc. has a 52-week low of $3.94 and a 52-week high of $14.34. The stock has a market cap of $63.67 million, a price-to-earnings ratio of -1.22 and a beta of 0.76. The business has a fifty day moving average of $5.79 and a two-hundred day moving average of $5.87.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. As a group, sell-side analysts anticipate that ImageneBio, Inc. will post -3.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IMA. Wedbush reiterated an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. Finally, Wall Street Zen cut shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, ImageneBio has a consensus rating of “Hold” and a consensus price target of $30.00.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.